Show simple item record

dc.contributor.authorReynolds, Kelly A
dc.contributor.authorSchlessinger, Daniel I
dc.contributor.authorVasic, Jelena
dc.contributor.authorIyengar, Sanjana
dc.contributor.authorQaseem, Yaqoob
dc.contributor.authorBehshad, Ramona
dc.contributor.authorDeHoratius, Danielle M
dc.contributor.authorDenes, Pablo
dc.contributor.authorDrucker, Aaron M
dc.contributor.authorDzubow, Leonard M
dc.contributor.authorEtzkorn, Jeremy R
dc.contributor.authorHarwood, Catherine
dc.contributor.authorKim, John Y S
dc.contributor.authorLee, Erica H
dc.contributor.authorLissner, Gary S
dc.contributor.authorMarghoob, Ashfaq A
dc.contributor.authorMatin, Rubeta N
dc.contributor.authorMattox, Adam
dc.contributor.authorMittal, Bharat B
dc.contributor.authorThomas, J Regan
dc.contributor.authorZhou, Xiaolong Alan
dc.contributor.authorZloty, David
dc.contributor.authorSchmitt, Jochen
dc.contributor.authorKirkham, Jamie
dc.contributor.authorPoon, Emily
dc.contributor.authorSobanko, Joseph F
dc.contributor.authorCartee, Todd V
dc.contributor.authorMaher, Ian A
dc.contributor.authorAlam, Murad
dc.date.accessioned2020-04-30T20:24:33Z
dc.date.available2020-04-30T20:24:33Z
dc.date.issued2020-01-15
dc.identifier.citationReynolds KA, Schlessinger DI, Vasic J, et al. Core Outcome Set for Actinic Keratosis Clinical Trials. JAMA Dermatol. 2020;156(3):326–333. doi:10.1001/jamadermatol.2019.4212en_US
dc.identifier.issn2168-6068
dc.identifier.pmid31939999
dc.identifier.doi10.1001/jamadermatol.2019.4212
dc.identifier.urihttp://hdl.handle.net/10150/641137
dc.description.abstractQuestion What are the most important outcomes to report in clinical trials on actinic keratosis? Findings In this survey study including physician and patient stakeholders (33 in round 1 and 29 in round 2), a consensus was reached regarding a core set of 6 of 137 outcomes and domains of actinic keratosis: complete clearance of actinic keratoses, percentage of actinic keratoses cleared, severity of adverse events, patient perspective on effectiveness, patient-reported future treatment preference, and rate of recurrence. Meaning In studies of treatment of actinic keratosis, the recommended core outcomes should be reported as a minimum to facilitate comparison of results across studies. This survey study assesses the most important outcomes to report in clinical trials on actinic keratosis based on Delphi surveys completed by physician and patient stakeholders. Importance Although various treatments have been found in clinical trials to be effective in treating actinic keratosis (AK), researchers often report different outcomes. Heterogeneous outcome reporting precludes the comparison of results across studies and impedes the synthesis of treatment effectiveness in systematic reviews. Objective To establish an international core outcome set for all clinical studies on AK treatment using systematic literature review and a Delphi consensus process. Evidence Review Survey study with a formal consensus process. The keywords actinic keratosis and treatment were searched in PubMed, Embase, CINAHL, and the Cochrane Library to identify English-language studies investigating AK treatments published between January 1, 1980, and July 13, 2015. Physician and patient stakeholders were nominated to participate in Delphi surveys by the Measurement of Priority Outcome Variables in Dermatologic Surgery Steering Committee members. All participants from the first round were invited to participate in the second round. Outcomes reported in randomized controlled clinical trials on AK treatment were rated via web-based e-Delphi consensus surveys. Stakeholders were asked to assess the relative importance of each outcome in 2 Delphi survey rounds. Outcomes were provisionally included, pending the final consensus conference, if at least 70% of patient or physician stakeholders rated the outcome as critically important in 1 or both Delphi rounds and the outcome received a mean score of 7.5 from either stakeholder group. Data analysis was performed from November 5, 2018, to February 27, 2019. Findings A total of 516 outcomes were identified by reviewing the literature and surveying key stakeholder groups. After deduplication and combination of similar outcomes, 137 of the 516 outcomes were included in the Delphi surveys. Twenty-one physicians and 12 patients participated in round 1 of the eDelphi survey, with 17 physicians (81%) retained and 12 patients (100%) retained in round 2. Of the 137 candidate outcomes, 9 met a priori Delphi consensus criteria, and 6 were included in the final outcomes set after a consensus meeting: complete clearance of AKs, percentage of AKs cleared, severity of adverse events, patient perspective on effectiveness, patient-reported future treatment preference, and recurrence rate. It was recommended that treatment response be assessed at 2 to 4 months and recurrence at 6 to 12 months, with the AK rate of progression to cutaneous squamous cell carcinoma reported whenever long-term follow-up was possible. Conclusions and Relevance Consensus was reached regarding a core outcome set for AK trials. Further research may help determine the specific outcome measures used to assess each of these outcomes.en_US
dc.language.isoenen_US
dc.publisherAMER MEDICAL ASSOCen_US
dc.rightsCopyright © 2020 American Medical Association. All rights reserved.en_US
dc.rights.urihttp://rightsstatements.org/vocab/InC/1.0/
dc.titleCore Outcome Set for Actinic Keratosis Clinical Trialsen_US
dc.typeArticleen_US
dc.contributor.departmentUniv Arizona, Coll Med, Div Dermatolen_US
dc.identifier.journalJAMA DERMATOLOGYen_US
dc.description.note12 month embargo; published online: 15 January 2020en_US
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.en_US
dc.eprint.versionFinal published versionen_US
dc.source.journaltitleJAMA dermatology
dc.source.countryUnited States


Files in this item

Thumbnail
Name:
jamadermatology_reynolds_2020_ ...
Size:
331.5Kb
Format:
PDF
Description:
Final Published Version

This item appears in the following Collection(s)

Show simple item record